Influence of atrial fibrillation on cardiac brain natriuretic peptide release during haemodynamic stress in heart failure

European Journal of Heart Failure

Volumn 8, Issue 3, 2006, Pages 263-269

  Gould, P A ^a   D'Agostino, J ^b   Schneider, H G ^b   Kaye, D M ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Atrial fibrillation; Brain natriuretic peptide; Heart failure

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTERIAL BLOOD; ARTICLE; CALCULATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY SINUS; DATA ANALYSIS; EXERCISE TEST; FEMALE; HAND GRIP; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FILLING; HEART RHYTHM; HEART STRESS; HUMAN; MALE; MUSCLE ISOMETRIC CONTRACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SINUS RHYTHM; STATISTICAL SIGNIFICANCE;

AGED; ATRIAL FIBRILLATION; BLOOD PRESSURE; EXERCISE; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; POSTURE;

EID: 33646350004     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2005.09.001     Document Type: Article

References (43)

1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20 1 (1992) 248-254
2. Cohn J.N., Levine T.B., Olivari M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 13 (1984) 819-823
3. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82 5 (1990) 1724-1729
4. Swedberg K., Eneroth P., Kjekshus J., and Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82 5 (1990) 1730-1736
5. Maeda K., Tsutamoto T., Wada A., Hisanaga T., and Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135 5 Pt 1 (1998) 825-832
6. Vanderheyden M., Goethals M., Verstreken S., et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 44 12 (2004) 2349-2354
7. Pfister R., Scholz M., Wielckens K., Erdmann E., and Schneider C.A. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 6 3 (2004) 289-293
8. Wang T.J., Larson M.G., Levy D., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109 5 (2004) 594-600
9. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. Jama 288 10 (2002) 1252-1259
10. Talwar S., Squire I.B., Downie P.F., et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J 21 18 (2000) 1514-1521
11. Latini R., Masson S., Anand I., et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106 19 (2002) 2454-2458
12. Silvet H., Young-Xu Y., Walleigh D., and Ravid S. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92 9 (2003) 1124-1127
13. Rossi A., Enriquez-Sarano M., Burnett Jr. J.C., Lerman A., Abel M.D., and Seward J.B. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 35 5 (2000) 1256-1262
14. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 7 (2004) 655-663
15. Matsumoto A., Hirata Y., Momomura S., et al. Effects of exercise on plasma level of brain natriuretic peptide in congestive heart failure with and without left ventricular dysfunction. Am Heart J 129 1 (1995) 139-145
16. de Groote P., Soudan B., Lamblin N., et al. Is hormonal activation during exercise useful for risk stratification in patients with moderate congestive heart failure?. Am Heart J 148 2 (2004) 349-355
17. McNairy M., Gardetto N., Clopton P., et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. Am Heart J 143 3 (2002) 406-411
18. Kruger S., Graf J., Merx M.W., et al. Brain natriuretic peptide kinetics during dynamic exercise in patients with chronic heart failure. Int J Cardiol 95 1 (2004) 49-54
19. Lainchbury J.G.S.M.P., Beckert L., et al. Change in plasma brain naturetic peptide during exercise is an important predictor of survival in systolic heart failure. Eur Heart J 22 (2001) 377 [Supplement]
20. Kaye D.M., Lambert G.W., Lefkovits J., Morris M., Jennings G., and Esler M.D. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 23 3 (1994) 570-578
21. Yao S.S., Moldenhauer S., and Sherrid M.V. Isometric handgrip exercise during dobutamine-atropine stress echocardiography increases heart rate acceleration and decreases study duration and dobutamine and atropine dosage. Clin Cardiol 26 5 (2003) 238-242
22. Storti S., Prontera C., Emdin M., et al. Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method. Clin Chem Lab Med 42 10 (2004) 1178-1185
23. McDonagh T.A., Cunningham A.D., Morrison C.E., et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86 1 (2001) 21-26
24. Berger R., Huelsman M., Strecker K., et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105 20 (2002) 2392-2397
25. Hammerer-Lercher A., Neubauer E., Muller S., Pachinger O., Puschendorf B., and Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 310 2 (2001) 193-197
26. Kazanegra R., Cheng V., Garcia A., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 7 1 (2001) 21-29
27. Pfister R., Scholz M., Wielckens K., Erdmann E., and Schneider C.A. The value of natriuretic peptides NT-pro-BNP and BNP for the assessment of left-ventricular volume and function. A prospective study of 150 patients. Dtsch Med Wochenschr 127 49 (2002) 2605-2609
28. Forfia P.R.W.S.P., Rame J.E., Stewart K.J., and Shapiro E.P. Relationship between B-type natriuetic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 45 10 (2005) 1667-1671
29. Brunner-La Rocca H.P., Kaye D.M., Woods R.L., Hastings J., and Esler M.D. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 37 5 (2001) 1221-1227
30. Hainsworth R. Reflexes from the heart. Physiol Rev 71 3 (1991) 617-658
31. Thomas C.J., Head G.A., and Woods R.L. Similar baroreflex bradycardic actions of atrial natriuretic peptide and B and C types of natriuretic peptides in conscious rats. J Hypertens 17 6 (1999) 801-806
32. Thomas C.J., May C.N., Sharma A.D., and Woods R.L. ANP, BNP, and CNP enhance bradycardic responses to cardiopulmonary chemoreceptor activation in conscious sheep. Am J Physiol Regul Integr Comp Physiol 280 1 (2001) R282-R288
33. Hansson M., and Forsgren S. Immunoreactive atrial and brain natriuretic peptides are co-localized in purkinje fibres but not in the innervation of the bovine heart conduction system. Histochem J 27 3 (1995) 222-230
34. Mills R.M., LeJemtel T.H., Horton D.P., et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 34 1 (1999) 155-162
35. Woods R.L., and Jones M.J. Atrial, B-type, and C-type natriuretic peptides cause mesenteric vasoconstriction in conscious dogs. Am J Physiol 276 5 Pt 2 (1999) R1443-R1452
36. Kostin S., Klein G., Szalay Z., Hein S., Bauer E.P., and Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 54 2 (2002) 361-379
37. Pemberton C.J.J.M.L., Yandle T.G., and Espiner E.A. Deconvolution analysis of cardiac natriuetic peptides during acute volume overload. Hypertension 36 3 (2000) 355-359
38. Wei T., Zeng C., Chen L., et al. Bedside tests of B-type natriuretic peptide in the diagnosis of left ventricular diastolic dysfunction in hypertensive patients. Eur J Heart Fail 7 1 (2005) 75-79
39. Lim H.S., Patel J.V., Nadar S., Hughes E.A., and Lip G.Y. Comparison of brain natriuretic peptide and left ventricular diastolic function determined by tissue Doppler in patients with diabetes mellitus, patients with hypertension without diabetes, and in healthy subjects. Am J Cardiol 95 7 (2005) 905-908
40. Mabuchi N., Tsutamoto T., Maeda K., and Kinoshita M. Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure. Jpn Circ J 64 10 (2000) 765-771
41. Espiner E.A., Richards A.M., Yandle T.G., and Nicholls M.G. Natriuretic hormones. Endocrinol Metab Clin North Am 24 3 (1995) 481-509
42. Matsui T., Tsutamoto T., and Kinoshita M. Relationship between cardiac 123I-metaiodobenzylguanidine imaging and the transcardiac gradient of neurohumoral factors in patients with dilated cardiomyopathy. Jpn Circ J 65 12 (2001) 1041-1046
43. Mukoyama M.N.K., Hosoda K., Saito Y., et al. Brain naturiuetic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual naturiuetic peptide system, atrial naturiuetic peptide and brain naturiuetic peptide. J Clin Invest 87 (1991) 1402-1412